In regard to the acquisition of Igenomix and the subsequent directed share issue, Vitrolife is presenting sales and preliminary income for the second quarter.
- Sales amounted to SEK 382 (209) million, corresponding to an increase of 83 percent in SEK. Sales increased by 94 percent in local currency.
- The preliminary operating income before depreciation and amortisation (EBITDA) amounted to SEK 134 (40) million, corresponding to a margin of 35 (19) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 15 million. The operating income included non-recurring acquisition-related costs of SEK 11 million and non-recurring transport-related costs of MSEK 3 million. Adjusted of these items, EBITDA amounted to MSEK 148 million, corresponding to a margin of 39 percent.
"It is gratifying to note that the recovery in demand has continued during the second quarter even though the rate of recovery varied between divisions and market regions", says Thomas Axelsson, CEO.
First half year
- Sales amounted to SEK 761 (543) million, corresponding to an increase of 40 percent in SEK. Sales increased by 49 percent in local currency.
- The preliminary operating income before depreciation and amortisation (EBITDA) amounted to SEK 297 (156) million, corresponding to a margin of 39 (29) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 25 million.
Complete information will be reported in connection with Vitrolife AB's regular interim report on July 15, 2021. No further information is intended to be released until then.
Gothenburg, 8 July, 2021
VITROLIFE AB (publ)
Thomas Axelsson, CEO
This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on July 8 2021 at 5.32 pm CET.
Show as PDF
Show original from Cision
This information was distributed by Cision http://www.cisionwire.se/